VIDEO: Novel vaccine shows benefit in VITAL for ovarian cancer
Click Here to Manage Email Alerts
In this video, Janos L. Tanyi, MD, PhD, discussed findings from the “very interesting” VITAL study that assessed the potential of a novel vaccine as front-line maintenance therapy for women with ovarian cancer.
Researchers randomly assigned patients who completed first-line treatment for ovarian cancer to vaccination or placebo in this phase 2b maintenance study. For those assigned vaccination, the researchers created an autologous vaccine using the patients’ own tumor cells that was injected into patients’ arms every 4 weeks up to 12 doses.
The results demonstrated considerable benefit with the vaccine, according to Tanyi.
“The vaccinated patients had a significantly better overall survival compared to the placebo arm patients,” he said.
Collapse
O’Malley DM, et al. Abstract 5504. Presented at: ASCO Annual Meeting (virtual meeting); June 4-8, 2021.
Read more about
Click Here to Manage Email Alerts